Shanghai Universal Biotech (301166)
- 27.99
- +1.48+5.58%
Shanghai Universal Biotech (301166) News
Recent portfolio adjustments by prominent fund managers reveal widening divergence in the pharmaceutical sector, with increased holdings in hard technology and power grid companies.
① Significant divergence emerged in portfolio adjustments within the pharmaceutical sector, with traditional generic drugmakers seeing net selling, while innovative drug and active pharmaceutical ingredient (API)-related stocks attracted increased holdings by public mutual funds; ② Zhong Shuai of China AMC added positions in semiconductor packaging and testing stocks, while Qi He of E Fund Management increased holdings in power grid equipment stocks; ③ Portfolio reallocations by well-known fund managers such as Zhang Kun, Hu Xinwei, and Zhou Weinan have become evident since Q2.
Uniwel (301166.SZ): Repurchased 19,100 shares for the first time
Gelonghui, June 2 — Youningwei (301166.SZ) announced that on June 2, 2026, the company repurchased 19,100 shares of its stock for the first time through a dedicated repurchase securities account via centralized bidding transactions, representing 0.0222% of the company’s current total share capital. The highest transaction price was RMB 28.00 per share, the lowest was RMB 27.93 per share, and the total transaction amount was RMB 534,528.00 (excluding transaction fees).
Uniwel (301166.SZ): Proposes to launch its first employee stock ownership plan
Gelonghui, May 27 — Youningwei (301166.SZ) announced its first employee stock ownership plan. The funding for this plan will be sourced from employees’ lawful compensation, self-raised funds, and other methods permitted by applicable laws and regulations. The company shall not provide any financial assistance to participants in the form of advances, guarantees, loans, or similar arrangements. The proposed aggregate amount of funds to be raised under this employee stock ownership plan shall not exceed RMB 14.739564 million (given that the company is currently implementing its 2025 equity distribution, the aforementioned upper limit of the proposed fundraising amount shall be calculated based on the post-ex-dividend and ex-rights share price, unless otherwise indicated). The subscription unit for this plan is denominated in 'units,' with each unit valued at RMB 1.00. Specific units
Express News | Uniwel: Plans to repurchase company shares worth RMB 15 million to RMB 30 million.
Youningwei (301166.SZ): Cumulative repurchase of 498,200 shares completed; repurchase plan fully implemented.
Gelonghui, May 13th: Youningwei (301166.SZ) announced that the actual repurchase period was from October 14, 2025, to May 12, 2026. As of the date of this announcement, the company has cumulatively repurchased 498,200 shares through a dedicated securities account for share repurchases via centralized bidding, accounting for 0.57% of the company’s total share capital. The highest transaction price per share was RMB 32.00, and the lowest was RMB 28.61. The total amount paid was RMB 15 million (excluding transaction fees). The repurchase period for the company's shares has now expired, and the repurchase amount has exceeded the amount specified in the repurchase plan.
Youningwei: First Quarter Report for 2026
Youningwei: 2025 Annual Report
U-NIV: Summary of the 2025 Annual Report
Youningwei (301166.SZ): The company currently has no plans for restructuring.
Gelonghui, April 22nd: Youningwei (301166.SZ) stated on the investor interaction platform that the company's controlling shareholder and actual controller remain firmly optimistic about the company’s development prospects and have no plans to transfer control. The company currently has no restructuring matters underway.
Youningwei (301166.SZ): The company's independent research and development efforts are primarily concentrated in the field of antibodies and antibody-related areas.
Gelonghui, April 22nd – Youningwei (301166.SZ) stated on the investor interaction platform that the company’s self-developed efforts are mainly concentrated in the field of antibodies and antibody-related areas. Currently, the company is primarily seeking relevant target enterprises in the upstream and downstream application fields of antibodies to achieve synergistic development with existing businesses. Additionally, through participation in equity investment funds, investments are directed towards sectors such as healthcare.
Youningwei (301166.SZ): Cumulative repurchase of 498,000 shares
Gelonghui, April 1st: Youningwei (301166.SZ) announced that as of March 31, 2026, the company had cumulatively repurchased 498,000 shares through its dedicated securities account for share repurchases via centralized bidding. These shares represent 0.57% of the company's total share capital. The highest transaction price was RMB 32.00 per share, and the lowest was RMB 28.61 per share. The total amount paid was RMB 15 million (excluding transaction fees).
Youningwei (301166.SZ): Cumulative repurchase of 390,000 shares
Gelonghui, March 2nd - Youningwei (301166.SZ) announced that as of February 28, 2026, the company had cumulatively repurchased 390,000 shares through its dedicated securities account for share repurchases via centralized bidding. These shares represent 0.45% of the company’s total share capital. The highest purchase price was RMB 31.00 per share, and the lowest was RMB 28.61 per share, with a total payment amounting to RMB 11.76 million (excluding transaction fees).
Youningwei: 2025 Annual Performance Forecast
Youningwei (301166.SZ): Cumulative repurchase of 0.45% of shares
Gelonghui, January 5th, Youningwei (301166.SZ) announced that as of December 31, 2025, the company has cumulatively repurchased 391,600 shares through the dedicated securities account for share repurchases via centralized bidding. These shares account for 0.45% of the company's total share capital. The highest transaction price was CNY 31.00 per share, and the lowest was CNY 28.61 per share. The total amount paid was CNY 11,760,373 (excluding transaction fees).
Univ-Bio (301166.SZ): Cumulative repurchase of 80,000 shares
Gelonghui, December 1 – UNIVIEW (301166.SZ) announced that as of November 30, 2025, the company had cumulatively repurchased 80,400 shares through its dedicated securities account for share repurchases via centralized bidding. These shares represent 0.09% of the company's total share capital. The highest purchase price was RMB 31.00 per share, and the lowest was RMB 30.46 per share. The total amount paid was RMB 2,475,786 (excluding transaction fees).
Unionway: Report for the third quarter of 2025
Univ-Bio (301166.SZ): Net loss of RMB 15.0796 million in the first three quarters
Gelonghui, October 29th丨Youningwei (301166.SZ) announced in its latest report that for the first three quarters of 2025, it achieved operating revenue of RMB 776 million, representing a year-on-year decrease of 6.24%; net profit attributable to shareholders of the listed company was -RMB 15.08 million, and net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was -RMB 30.27 million. Basic earnings per share were -RMB 0.17.
Express News | Youningwei: As of August 31, 2025, the company has not yet implemented this share repurchase.
Youningwei (301166.SZ): Received government subsidy of 5.13 million yuan.
Gelonghui, August 27 - Youningwei (301166.SZ) announced that the company recently received government subsidies amounting to 5.13 million yuan, accounting for 50.55% of the audited net profit attributable to the parent company's shareholders for the fiscal year 2024.
Unionway: 2025 Semi-Annual Report Summary